Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
On November 28, 2016, Blueprint Medicines Corporation (the
Company) issued a press releaseannouncing initial data from the
dose escalation stage of its ongoing Phase 1 clinical trial
evaluating BLU-554for the treatment of advanced hepatocellular
carcinoma.BLU-554 is an orally available, potent and highly
selective inhibitor that targets the kinase FGFR4. A copy of the
press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K.The Company is presenting the data on Tuesday,
November 29, 2016, in a poster presentation at the 28th
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics in Munich, Germany.
The information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1 attached hereto, is intended to be
furnished and shall not be deemed filed for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press release issued by Blueprint Medicines Corporation |
2
About Blueprint Medicines Corporation (NASDAQ:BPMC)
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC). Blueprint Medicines Corporation (NASDAQ:BPMC) Recent Trading Information
Blueprint Medicines Corporation (NASDAQ:BPMC) closed its last trading session 00.00 at 35.50 with 94,963 shares trading hands.
